(Q37995404)

26 August 2017

title

Roflumilast: a novel treatment for chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

26 August 2017

main subject

1 reference

1 reference

ChEBI release 2020-05-28

Debra J Reid

1

1 reference

26 August 2017

Nga T Pham

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

20 March 2012

1 reference

Annals of Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

46

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

521-529

1 reference

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

26 August 2017

cites work

1 reference

Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population

21 January 2018

1 reference

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

21 January 2018

1 reference

PDE4 inhibitors - a review of the current field

21 January 2018

1 reference

PDE4 inhibitors: a review of current developments (2005 - 2009).

21 January 2018

1 reference

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

21 January 2018

1 reference

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor

21 January 2018

1 reference

ABCD of the phosphodiesterase family: interaction and differential activity in COPD

21 January 2018

1 reference

Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.

21 January 2018

1 reference

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

21 January 2018

1 reference

Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects

21 January 2018

1 reference

Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide

21 January 2018

1 reference

A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1Q646

1 reference

26 August 2017

1 reference